Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORKA-002 in Healthy Participants
NCT06944379Phase 1Completed
- Sponsor
- Oruka Therapeutics
- Start
- May 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing ORKA-002 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-emergent Adverse Events at 1 year. Started May 2025; status: completed.
02
Drugs
ORKA-002
Beyond the preview
Go deeper on NCT06944379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06944379.